SAN DIEGO, California — November 24, 2025 — Leads & Copy — iBio, Inc., an AI-driven innovator of precision antibody therapies, announced its participation in the 8th Annual Evercore Healthcare Conference in Miami, December 2–4, 2025.
Martin Brenner, DVM, Ph.D., iBio’s Chief Executive Officer and Chief Scientific Officer, will participate in a fireside chat on Thursday, December 4, 2025, at 8:45 a.m. ET. Brenner will outline the company’s efforts to advance its next-generation obesity pipeline into clinical development.
He will highlight promising new non-human primate data for IBIO-610, a potential first-in-class Activin E antibody, which was presented at ObesityWeek® 2025.
Felipe Duran, iBio’s Chief Financial Officer, will join Brenner for one-on-one meetings during the conference.
A live stream of the event can be accessed via a link provided in the release. A replay will be available in the Investor section of the iBio website.
iBio is leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer, and other hard-to-treat diseases. The company combines proprietary 3D modeling with innovative drug discovery platforms to create breakthrough antibody treatments.
iBio’s mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine.
Forward-looking statements in the press release are based on current estimates and assumptions regarding the company’s continued development, progress across its obesity pipeline, and the therapeutic potential of Activin E as a target for cardiometabolic disorders and obesity.
These statements also address IBIO-610 preclinical data predicting a human half-life of up to 100 days, suggesting potential dosing as infrequently as twice per year, and participation in the Evercore Healthcare Conference.
These forward-looking statements are subject to risks and uncertainties, including the ability to commence clinical trials, the success of antibody programs, iBio’s ability to obtain regulatory approvals, market acceptance of product candidates, and unforeseen expenses or liabilities.
iBio undertakes no obligation to update these statements, except as required by law.
Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio
Felipe Duran, iBio’s Chief Financial Officer
Ignacio Guerrero-Ros, Ph.D., Russo Partners, LLC, Ignacio.guerrero-ros@russopartnersllc.com, (858) 717-2310
David Schull, Russo Partners, LLC, David.schull@russopartnersllc.com, (646) 942-5604
Investor Relations, ir@ibioinc.com
Source: iBio, Inc.
